The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

BioArctic’s partner Eisai announces update on regulatory review of lecanemab to treat early Alzheimer’s disease in EU: Stockholm Monday, February 3, 2025, 13:00 Hrs [IST] BioA ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

You can install Opentelemetry Operator via Helm Chart from the opentelemetry-helm-charts repository. More information is available in here. WARNING: Until the ...

Your browser does not support the audio element. India’s premier motor show, the Auto Expo 2025, is underway, and some big names have shown important models ...

If you’re looking for auto insurance reviews, you’ve come to the right place. NerdWallet has researched policy options, consumer complaint data, customer satisfaction ratings, financial ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act ...

LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector (AI). The injection process is expected to take, on average, 15 seconds. As part of the ...